Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2007;38:204-205
Published online before print November 16, 2006, doi: 10.1161/01.STR.0000251797.86897.a3
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/1/204    most recent
01.STR.0000251797.86897.a3v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Al-Shahi, R.
Right arrow Articles by You, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Shahi, R.
Right arrow Articles by You, H.
Related Collections
Right arrow Acute Cerebral Hemorrhage
Right arrow Emergency treatment of Stroke
Right arrow Intracerebral Hemorrhage
Right arrow Other Stroke Treatment - Medical

(Stroke. 2007;38:204.)
© 2007 American Heart Association, Inc.


Cochrane Corner

Hemostatic Drug Therapies for Acute, Nontraumatic Intracerebral Hemorrhage

Rustam Al-Shahi, MA, PhD, MRCP(UK) Hong You, MD

From the Division of Clinical Neurosciences, Centre for Clinical Brain Sciences, School of Molecular and Clinical Medicine, University of Edinburgh, UK.

Correspondence to Dr Rustam Al-Shahi, MA PhD MRCP(UK), MRC clinician scientist, Bramwell Dott Building, Division of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK. E-mail Rustam.Al-Shahi{at}ed.ac.uk

Section Editor: Graeme J. Hankey MD, FRCP


Key Words: acute cerebral hemorrhage • intracerebral hemorrhage • emergency treatment of stroke • other stroke treatment, medical


*    Introduction
up arrowTop
*Introduction
down arrowObjective
down arrowSearch Strategy
down arrowSelection Criteria
down arrowData Collection and Analysis
down arrowMain Results
down arrowImplications for Clinical...
down arrowImplications for Research
down arrowReferences
 
Because nontraumatic intracerebral hemorrhage (ICH) volume strongly influences its outcome and a third of ICHs enlarge by a third within 24 hours of onset, hemostatic drug therapy given very soon after ICH onset might improve outcome.


*    Objective
up arrowTop
up arrowIntroduction
*Objective
down arrowSearch Strategy
down arrowSelection Criteria
down arrowData Collection and Analysis
down arrowMain Results
down arrowImplications for Clinical...
down arrowImplications for Research
down arrowReferences
 
We sought to determine the clinical effectiveness and safety of hemostatic drug therapies for acute nontraumatic ICH in randomized controlled trials (RCTs).


*    Search Strategy
up arrowTop
up arrowIntroduction
up arrowObjective
*Search Strategy
down arrowSelection Criteria
down arrowData Collection and Analysis
down arrowMain Results
down arrowImplications for Clinical...
down arrowImplications for Research
down arrowReferences
 
In August 2005 we searched the Cochrane Stroke Group Trials Register, the Cochrane Central Register of Controlled Trials, MEDLINE from 1966 and EMBASE from 1980. We also scanned bibliographies of relevant articles, searched international registers of clinical trials and research, and contacted authors and pharmaceutical companies.


*    Selection Criteria
up arrowTop
up arrowIntroduction
up arrowObjective
up arrowSearch Strategy
*Selection Criteria
down arrowData Collection and Analysis
down arrowMain Results
down arrowImplications for Clinical...
down arrowImplications for Research
down arrowReferences
 
We sought randomized controlled trials of any hemostatic drug therapy for acute nontraumatic ICH, compared against placebo or open control, with relevant clinical outcome measures.


*    Data Collection and Analysis
up arrowTop
up arrowIntroduction
up arrowObjective
up arrowSearch Strategy
up arrowSelection Criteria
*Data Collection and Analysis
down arrowMain Results
down arrowImplications for Clinical...
down arrowImplications for Research
down arrowReferences
 
Two review authors (R.A.-S., H.Y.) independently applied the inclusion criteria, reviewed the relevant studies, and extracted data from them.


*    Main Results
up arrowTop
up arrowIntroduction
up arrowObjective
up arrowSearch Strategy
up arrowSelection Criteria
up arrowData Collection and Analysis
*Main Results
down arrowImplications for Clinical...
down arrowImplications for Research
down arrowReferences
 
We found 4 phase II RCTs, involving adults aged 18 years or over, within 4 hours of nontraumatic ICH. One hundred and sixteen study participants received placebo and 373 received hemostatic drugs (2 received {varepsilon}-aminocaproic acid and 371 received recombinant activated factor VII [rFVIIa]).

Hemostatic drugs reduced the relative risk of death within 90 days of nontraumatic ICH (risk reduction [RR] 0.67; 95% CI, 0.46 to 0.97, random effects; Figure). Specifically, rFVIIa appeared to reduce the risk of death or dependence on the modified Rankin Scale (grades 4 to 6) within 90 days of nontraumatic ICH (RR 0.79; 95% CI, 0.67 to 0.93) but not when assessed by the extended Glasgow Outcome Scale (RR 0.90; 95% CI, 0.81 to 1.01). A statistically significant excess of arterial thromboembolism at 160-µg/kg rFVIIa has been found in the trials (odds ratio 7.17, P=0.0004 versus placebo1).


Figure 1470013
View larger version (10K):
[in this window]
[in a new window]

 
Effect of hemostatic drugs compared with placebo or open control on death at 90 days of follow-up in patients with acute, nontraumatic intracerebral hemorrhage. ATICH was a trial of {varepsilon}-aminocaproic acid


*    Implications for Clinical Practice
up arrowTop
up arrowIntroduction
up arrowObjective
up arrowSearch Strategy
up arrowSelection Criteria
up arrowData Collection and Analysis
up arrowMain Results
*Implications for Clinical...
down arrowImplications for Research
down arrowReferences
 
The evidence for the use of hemostatic drugs in the treatment of acute ICH is insufficient to provide clear guidelines for practice but should influence priorities for research.


*    Implications for Research
up arrowTop
up arrowIntroduction
up arrowObjective
up arrowSearch Strategy
up arrowSelection Criteria
up arrowData Collection and Analysis
up arrowMain Results
up arrowImplications for Clinical...
*Implications for Research
down arrowReferences
 
The clinical benefits of hemostatic drugs for acute nontraumatic ICH that have been observed among the secondary outcomes in phase II RCTs have led to a large phase III RCT of rFVIIa (FAST trial, NCT00127283). The FAST trial must (1) confirm or refute the apparent effects of rFVIIa on death or dependence and (2) provide more reliable evidence on whether any benefit from reduced hematoma growth is offset by an increase in arterial and venous thromboembolic events.

Evidence of the effects of less costly hemostatic drugs (for example, aprotinin, tranexamic acid, and {varepsilon}-aminocaproic acid) in other clinical settings suggests that these drugs are also worth testing in large RCTs in people with acute nontraumatic ICH.

Note: The full text of this review is available in the Cochrane Library (for subscribers http://www.mrw.interscience.wiley. com/cochrane/clsysrev/articles/CD005951/frame.html). The full article should be cited as: You H, Al-Shahi R. Hemostatic drug therapies for acute primary intracerebral hemorrhage. Cochrane Database of Systematic Reviews. 2006, Issue 3. Art. No.: CD005951. DOI: 10.1002/14651858.CD005951.pub2.


*    Acknowledgments
 
We are grateful to Professor Christopher Ludlam (University of Edinburgh) and members of the Cochrane Stroke Review Group for their comments on the manuscript.

Sources of Funding

This review was funded by the China Scholarship Council and GanSu Province Peoples’ Hospital (to H.Y.) and a UK Medical Research Council Clinician Scientist Fellowship (to R.A.S.).

Disclosures

None.

Received September 3, 2006; accepted September 10, 2006.


*    References
up arrowTop
up arrowIntroduction
up arrowObjective
up arrowSearch Strategy
up arrowSelection Criteria
up arrowData Collection and Analysis
up arrowMain Results
up arrowImplications for Clinical...
up arrowImplications for Research
*References
 

  1. Diringer MN, Selchen D, Davis S, Mayer SA, Brun NC, Broderick J, Skolnick BE, Steiner T; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Safety profile of recombinant factor VIIa in patients with intracerebral hemorrhage. Stroke. 2006; 37: 623. Abstract.




This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/1/204    most recent
01.STR.0000251797.86897.a3v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Al-Shahi, R.
Right arrow Articles by You, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Shahi, R.
Right arrow Articles by You, H.
Related Collections
Right arrow Acute Cerebral Hemorrhage
Right arrow Emergency treatment of Stroke
Right arrow Intracerebral Hemorrhage
Right arrow Other Stroke Treatment - Medical